Enanta Pharmaceuticals Inc (ENTA)

[floblu14]

ENANTA PHARMACEUTICALS PRESENTS NEW DATA FROM ITS HEPATITIS B AND NON-ALCOHOLIC STEATOHEPATITIS PROGRAMS AT THE DIGITAL INTERNATIONAL LIVER CONGRESS™ 2020

AUGUST 28, 2020

New Pharmacokinetic and Safety Results from Phase 1a Study of HBV Core Inhibitor EDP-514, Highlighting Good Safety and Tolerability, and Pharmacokinetics Suitable for Once Daily Dosing
Phase 2a ARGON-1 Study for FXR Agonist EDP-305 Targeting NASH, Showing Significant Alanine Transaminase and Liver Fat Content Reduction

Preclinical Findings for Follow-on FXR Agonist EDP-297 Targeting NASH, Demonstrating Potent Anti-Fibrotic, Anti-Inflammatory and Hepatoprotective Effects

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced that data from Enanta’s wholly-owned development programs for non-alcoholic steatohepatitis (NASH) and hepatitis B virus (HBV) will be presented at the European Association for the Study of the Liver (EASL) Digital International Liver Congress™ 2020.

Data presented include results from the Phase 1a clinical trial of EDP-514, Enanta’s core inhibitor for HBV. Additionally, Enanta’s NASH program will be discussed in an oral presentation detailing the Phase 2a ARGON-1 study of EDP-305, Enanta’s lead Farnesoid Xreceptor (FXR) agonist, and two posters highlighting preclinical data on EDP-297, Enanta’s follow-on FXR agonist.

“We are pleased to share scientific data across multiple candidates in our pipeline, supporting our chemistry-driven approach to developing innovative treatments for viral infections and liver diseases,” stated Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta Pharmaceuticals. “The positive results from our first-in-human Phase 1a study of EDP-514, demonstrating a strong safety, tolerability and pharmacokinetic profile, gave us the confidence to advance our HBV program into two ongoing Phase 1b clinical studies in HBV patients. Additionally, the data presented for our NASH candidates further demonstrate the potential of both FXR agonists. EDP-305 shows statistically significant improvements in liver biochemistry and hepatic steatosis, and our follow-on NASH candidate EDP-297 demonstrates a potent anti-fibrotic effect.”

August 28, 2020, 12:15 PM - 12:30 PM CEST

Additional - Read more:
https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Presents-New-Data-from-its-Hepatitis-B-and-Non-Alcoholic-Steatohepatitis-Programs-at-the-Digital-International-Liver-Congress-2020/default.aspx